Leading In-House Speakers
Isabelle Gundel
Senior Patent AttorneyHaleon
Agnieszka Deeg-Tyburska
General CounselPolpharma
Michal Porubsky
Senior Litigation CounselNovo Nordisk
Andreas Robinson
Senior Counsel Intellectual Property & LitigationAmgen
Rachel Goode
Senior Vice President, Legal and Intellectual Property, BiopharmaceuticalsFresenius Kabi
Laila Beynon
AD- Dispute ResolutionRegeneron
Julia Pike
Global Head of IPSandoz
Adrian Spillmann
Director of Intellectual PropertyValneva- Michal Porubsky
Senior Litigation CounselNovo Nordisk
Leading Judicial and Regulatory Speakers
Dr Oliver Werner
Head Patent Department, Head SPC Working GroupGerman Patent and Trade Mark Office
Dr Martijn de Lange
Patent ExaminerNetherlands Patent Office
Dolores Cassidy
Head of Patent/SPC ExaminationIntellectual Property Office of Ireland
Sabine Klepsch
Honourable JudgeUPC Local Division Hamburg
Boris Andrejas
Case HandlerDG Comp
Elodie Ferraty
Head of Chemistry DivisionINPI
DOWNLOAD THE 2024 EVENT AGENDA
After a huge meeting in 2023, the Life Sciences Strategy Summit on IP & Exclusivity is returning to Munich again to review the latest Regulatory Exclusivity Strategies and legal challenges for pharmaceutical, biotech & medical device companies.
The 2024 event agenda is now ready! Fill out this short form to recieve your copy featuring a star-studded line-up of 45+ speakers.
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick above.
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
By clicking submit below, you consent to allow Kisaco Research to store and process the personal information submitted above to provide you the content requested.
2024 EVENT AGENDA IS NOW READY
Leading Private Practice Speakers
Marco Stief
PartnerMaiwald
Judith Krens
PartnerPinsent Masons
Tobias Wuttke
PartnerBardehle Pagenberg
Christina Thomson
Managing AssociateSimmons & Simmons
Claudia Milbradt
PartnerClifford Chance
Agathe Michel-De-Cazotte
PartnerCarpmaels & Ransford
Lora Green
PartnerGemini Law
Denis Schertenleib
PartnerSchertenleib Avocats
Paul Calvo
DirectorSterne Kessler
Don't Just Take Our Word For It, Here Is What The Community Has To Say
Great event with insightful presentations and panels. I learned a lot and met very knowledgeable people. The event was well organized.
Senior Patent Counsel, European Patent Attorney, AbbVie
Very interesting topics were discussed that were spot-on relevant for my daily work as a life science patent attorney.
Counsel Patent Attorney, Bird & Bird
Good overview of the ongoing challenges and proposals in EU with regards to UPC, SPC and Regulatory, preempting Generics to roll up their sleeves.
Head of IP, Genepharm SA
The Summit gave a good overview and an opportunity to hear and discuss the latest insights on IP and exclusivity for Life Science. I liked that all relevant parties were present to share their views.
Patent Attorney, NLO
A really well organised event with an excellent selection of relevant talks and great networking opportunities.
Senior Director of Patents, Norgine
This is a serious conference and was attended by IP attorneys and in house counsels. The topics taken were very relevant and it was a very good experience. The round table discussion was also good.
Partner, Remfry & Sagar
The speakers were well coordinated so little overlap but good integration of the topics. I came away with a better understanding of the topics presented.
General Counsel, Morphic Therapeutics
Excellent speakers and highly relevant topics made for a thoroughly worthwhile conference.
Senior Legal Counsel, European Intellectual Property and Regulatory Litigation, Teva Pharmaceuticals
Informative breadth of multidisciplinary topics which are rarely fused together into a single conference elsewhere. Provided useful insights from the perspectives of different domains.
Intellectual Property Consultant, TRON
I have already recommended the event to colleagues. I particularly liked the presentations on the SPC waivers and on the proposals for unitary SPCs and the amended SPC Regulations as well as the national examiners' session.
Partner, Hoffmann Eitle
I had the privilege of attending the Life Sciences Strategy Summit 2023, and it was an invaluable experience. The event brought together a diverse and knowledgeable community of professionals, fostering insightful discussions on the latest trends and strategies in the life sciences industry. The engaging sessions and networking opportunities provided a unique platform to connect with experts and peers, contributing to a richer understanding of the field. I'm grateful for the opportunity to be part of this vibrant community, and I look forward to future events.
Patent Opposition & Litigation Executive, Sanovel
The event was perfectly suitable for the professionals who have expertise in life science. All speakers and attendees were highly qualified and experienced in diverse fields of IP.
Partner, INVOKAT Intellectual Property Services
A fantastic forum with expert speakers and attendees gathered to learn about the most important topics in IP and exclusivity in the life sciences. The schedule provides plants of networking opportunities to supplement the excellent subject matter content.
Vice President, IP, Vaccitech Ltd.
This event is bringing together in-house counsels and law professionals from the main countries and is focusing directly on the current trending topics in the IP-Pharma industry, which is very valuable to both sides.
Director, Intellectual Property, Adalvo
Kisaco's event on Life Sciences is becoming a real central moment for the IP European community. The organisation is great and the panels very well organized and dedicated. The participants are the best players in the field.
Partner, Pavia e Ansaldo
LIFE SCIENCES PATENT ADVISORY BOARD
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Associate General Patent Counsel
UCB
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counse
Novartis
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Group Head IP Counsel
Recordati
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Philip Caramanica
Chief IP Counsel & Deputy General Counsel
Alvotech
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Associate General Patent Counsel
UCB
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counse
Novartis
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Group Head IP Counsel
Recordati
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Philip Caramanica
Chief IP Counsel & Deputy General Counsel
Alvotech
LIFE SCIENCES STRATEGY SUMMIT 2023 COMMUNITY
From our advisory board and speakering faculty to our media and strategic partners, our series wouldn't be possible without the contributions of Our esteemed community of in-house IP counsel, private practice and regulatory leaders.
2023 SPEAKERS
Adrian Chew
Of Counsel
Bristows
Adrian Spillmann
Director of Intellectual Property
Valneva
Agathe Michel-De-Cazotte
Partner
Carpmaels & Ransford
Agnieszka Deeg-Tyburska
General Counsel
Polpharma
Ana Lopez Lozano
Lead Patent Counsel
Zentiva
Andre Andrade
Vice President, Client Relations EMEA and Law Firms,
RWS
Andreas Robinson
Senior Counsel Intellectual Property & Litigation
Amgen
Anna Wolters-Hoehne
Partner
A & O Shearman
Anna is a highly experienced patent litigator advising primarily life sciences clients in global patent disputes. With about 20 years of practice in leading and coordinating high profile patent cases Anna develops both offensive and defensive patent strategies for her clients to protect their product portfolio nationally and in an international context.
Anna’s long-standing expertise covers patent infringement and preliminary injunction proceedings as well as patent damages proceedings before the German courts. She also advises on national compulsory licence cases and nullity actions as well as EPO opposition proceedings and the UPC. Anna regularly coordinates international patent disputes and advises clients in particular from the innovative pharmaceutical and medical device industries.
Axel Berger
Partner
Bardehle
Betsy Flanagan
Partner
Cooley
Bianca Vos
Partner
Hoffmann Eitle
Boris Andrejas
Case Handler
DG Comp
Brian Coggio
Counsel
Fish & Richardson
Cecile Teles
Head of IP
Zentiva
Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.
Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.
Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.
Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.
Charlotte Weekes
Partner
Pinsent Masons
Christina Brown-Marshall
Principal
Fish & Richardson
Christina Thomson
Managing Associate
Simmons & Simmons
Christof Bull
Associate General Patent Counsel
UCB
Christoph Rehfuess
Head of IP
Sotio
Claudia Milbradt
Partner
Clifford Chance
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Denis Schertenleib
Partner
Schertenleib Avocats
Dolores Cassidy
Head of Patent/SPC Examination
Intellectual Property Office of Ireland
Dolores Cassidy, B.Sc. Ph.D., graduated from University College Dublin with a Ph.D. in Physical Chemistry. In 1998 she joined the Intellectual Property Office of Ireland as a Patent Examiner, with particular responsibility for the examination of Supplementary Protection Certificates (SPCs). In 2021 she was promoted to the position of Head of Patent/SPC Examination at the Irish Office.
Dorian Immler
Head of Patents
Bayer
Eduardo Hallak
Partner
Licks Attorney
Eduardo Hallak is one of the founding partners at Licks Attorneys and one of our leaders at the Sao Paulo office. For more than a decade, he has been working as a litigator before state and federal courts in Brazil in several complex disputes and leading cases involving Patent law, competition, and regulatory compliance, most of them pursuing the interests of clients in the area of life sciences. He also has extensive practice in trademark litigation as well as technology transfer contracts, working together with multinational clients to establish strong brand protection and licensing programs in the country. Mr. Hallak also currently teaches IP litigation in the Post-Graduation course at the prestigious Pontifical Catholic University of Rio de Janeiro (PUCRJ), has taught Civil Procedure at the at the Brazilian Association of IP Agents (ABAPI), and is often invited to lecture on procedural and strategic aspects of IP litigation, in addition to being a member of the Special Commission on Mediation of the Rio de Janeiro Chapter of the Brazilian Bar Association (OABRJ) and the Enforcement Committee of INTA.
Elodie Ferraty
Head of Chemistry Division
INPI
Eva Ehlich
Partner
Maiwald
Filipe Pedro
Director of IP
BIAL
Florian Bechtel
Senior Counsel- Digital & Device IP
Sanofi
Fritz Gerritzen
Partner
A & O Shearman
Gemma Barrett
Partner
A & O Shearman
Gemma is an experienced and trusted advisor for some of the world’s leading life sciences and chemical companies. Her background in biochemistry means she specialises in complex technical disputes in the life sciences sector. She has more than fifteen years’ experience advising clients in patent litigation matters before the English Courts including securing preliminary injunctions. She is also experienced in advising on global cross-border litigation, and coordinating worldwide litigation, working closely with multi-disciplinary teams in the defence and enforcement of patent portfolios. She has developed innovative and successful strategies, often combining patent and regulatory law, to assist pharmaceutical companies in the enforcement of their rights.
Geoff Biegler
Partner
Cooley
Ha Kung Wong
Partner, Advisory Board Member
Venable, Centre for Biosimilars
Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr. Wong also has extensive experience with Inter Partes Review, Post Grant Review, intellectual property counseling, pharmaceutical regulatory counseling, pre-suit investigations, licensing, and due diligence.
Mr. Wong has his BS with high distinction in Chemistry and his BS in Biochemistry from the University of Illinois Urbana-Champaign and his JD, cum laude, from the University of Notre Dame. Mr. Wong is currently an elected member of the Venable Board, is an Advisory Board Member for the Center for Biosimilars, is Treasurer, Executive Committee member, and Board Trustee for the Foundation for Advancement of Diversity in IP Law (FADIPL) and serves as faculty for the National Institute of Trial Advocacy (NITA) and Lawline.
Hilary Pioro
Senior Patent Counsel
Polpharma Biologics
Isabelle Gundel
Senior Patent Attorney
Haleon
Isobel Barry
Partner
Carpmaels & Ransford
James Horgan
Chief IP Counsel
MSD
Jiri Slavik
Director of IP
Adalvo
Judith Krens
Partner
Pinsent Masons
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Karin Pramberger
Head of IP
Polpharma Group
Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva. She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam.
Katherine Helm
Partner
Dechert
Katie Rooth
Lead IP Litigation Counsel
Sandoz
Kaushal Joshi
Senor Director Legal, IP and Product Portfolio
Kashiv Biosciences
Kora Knuchel
Vice President, IP & Legal
Bruker
Laila Beynon
AD- Dispute Resolution
Regeneron
Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT.
Lora Green
Partner
Gemini Law
Prior to joining Gemini, Lora was a senior partner at Wilson, Sonsini, Goodrich & Rosati, as part of the firm’s PTAB practice group.
Before entering private practice, Lora was a Lead Administrative Patent Judge at the U.S. Patent & Trademark Office, as well as a primary patent examiner in the pharmaceutical and biotechnology examining groups. While at the USPTO, she managed post-grant review proceedings, such as inter partes and post grant reviews.
Manja Epping
Partner
Taylor Wessing
As a lawyer specialising in pharmaceutical and IP law, Manja has been advising pharmaceutical and biotechnology companies, medical device manufacturers, and food producers on all matters relating to intellectual property and regulatory questions for many years. One of her areas of expertise is regulatory data and market protection as well as orphan drug exclusivity, where she has a track record of representing clients before German and EU courts. Another focus of her practice involves advising clients on complex contractual projects, in particular, research and development cooperations, manufacturing agreements, distribution agreements and licence agreements.
Marco Stief
Partner
Maiwald
Margaret O'Gara
Director of IP
Nanobiotix
Margaret is a French and European patent attorney currently heading IP at a late development stage biotech in Paris, called Nanobiotix.
She started her professional career as a researcher in the pharma industry in the UK and France, before moving into patents in 2004.
Since then she has worked both in-house and in IP firms and spent nearly ten years with Santarelli before taking the IP position at Nanobiotix early 2020. Margaret has considerable experience in all aspects of European patent prosecution, and post grant proceedings, as well as strategies for filing new applications . She is interested in data exclusivity and prolonging the protection of innovative products.
Maria Lamottke
VP Business Development
Biocoll
Marius-Benjamin Schneider
Head of Legal
Insempra
Dr Martijn de Lange
Patent Examiner
Netherlands Patent Office
Martin Schmidt
Life Science Technical Judge
UPC
Max Haedicke
Honourable Judge
Paris Central Division
Michal Porubsky
Senior Litigation Counsel
Novo Nordisk
Mortiz Ammelberg
Principal
Fish & Richardson
Nicholas Mitrokostas
Partner
A & O Shearman
Nick is the Managing Partner of the Boston office and an experienced Life Sciences trial attorney who focuses on representing innovator companies in intellectual property, trade secret, licensing and antitrust disputes. A litigator known for his trial skills, Nick has been lead counsel and gone to trial in dozens of ANDA and BPCIA litigations and has extensive experience representing clients in the pharmaceutical, biotechnology, and medical device industries in federal and state courts as well as before the Patent Trial and Appeal Board (PTAB). Nick also has expertise in counseling emerging and small and mid-cap Life Sciences companies in late stage drug development on issues pertaining to patent and regulatory exclusivities including patent term extension (PTE), patent listing requirements, and pre-commercial and launch assessments and litigation risks.
Dr Oliver Werner
Head Patent Department, Head SPC Working Group
German Patent and Trade Mark Office
Patrick Heckeler
Partner
Bardehle
Paul Calvo
Director
Sterne Kessler
Pedro Roman
IP Counsel
Insud Pharma
Petra Bohanec Grabar
IP Lead
Sandoz
Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg.
Petra has extensive experience working in house. In her current role as Group Head in Sandoz, Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets.
Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.
Roberto Romandini
Legal Member of the Board of Appeal
EPO
Roberto Romandini obtained his law degree from the University of Pisa and his LL.M. degree from the University of Munich, where he specialized in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the Max Planck Institute in Munich before practicing IP law at a leading IP law firm in Milan for 5 years. From 2013 he was a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich. Since 2019 he has been a legal member at the Boards of Appeal at the EPO.
Robin Ellis
Partner
Reddie&Grose
Sabine Klepsch
Honourable Judge
UPC Local Division Hamburg
Sara Burghart
Senior Counsel- Patent Litigation
BAT
Sherry Yao
Partner
King & Wood Mallesons
Stefania Bergia
Partner
Simmons
Stefanie Kies
Senior Director Intellectual Property
Polpharma Biologics
Stephen Reese
Partner
Clifford Chance
Suzanne Renes
European Patent Attorney
Sanofi
Suzanne graduated Cum Laude from Amsterdam University College in 2015 with a BSc in Biomedical Sciences. In 2016 she graduated from University College London with an MSc in Pharmaceutical Formulation and Entrepreneurship. She is a qualified Dutch and European Patent Attorney that started her career in the Pharma team at NLO in 2018. Since January 2022 she has been employed in the Ablynx team of Sanofi in Ghent, where she has been working as a patent attorney specializing in immunoglobulin single variable domains (camelid-derived VHH). In her free time, she enjoys learning new languages, playing badminton and dancing salsa.
Tamaris Bucher
Principal Patent Attorney
Novartis
Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.
She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.
Tamaris is both a registered European Patent Attorney and Swiss Patent Attorney. Additionally, she has a background in Australian patent law, having completed a Master of Industrial Property at the University of Technology, Sydney.
Tobias Wuttke
Partner
Bardehle Pagenberg
BOOK YOUR PLACE TODAY
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
We accept the following cards through Stripe:
Ticket price will increase after
— —
- Wednesday, May 1, 2024 to Saturday, June 29, 2024Tier 1 - In-House€599Super Super Early Bird Pricing - Register before 28th June to save €400Exclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, June 29, 2024 to Saturday, August 3, 2024Tier 1 - In-House€799 + VATSuper Early Bird Pricing - Register before 2nd August to save €200Exclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, August 3, 2024 to Saturday, September 14, 2024Tier 1 - In-House€899 + VATEarly Bird Pricing - Register before 6th September to save €100Exclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, September 14, 2024 to Thursday, October 10, 2024Tier 1 - In-House€999 + VATStandard PricingExclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Wednesday, May 1, 2024 to Saturday, June 29, 2024Tier 2 - Law Firms€1399 + VATSuper Super Early Bird Pricing - Register before 28th June to save €900Exclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, June 29, 2024 to Saturday, August 3, 2024Tier 2 - Law Firms€1699 + VATSuper Early Bird Pricing - Register before 2nd August save €600Exclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, August 3, 2024 to Saturday, September 14, 2024Tier 2 - Law Firms€1999 + VATEarly Bird Pricing - Register before 6th September to save €300Exclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, September 14, 2024 to Thursday, October 10, 2024Tier 2 - Law Firms€2299 + VATStandardExclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Wednesday, May 1, 2024 to Saturday, June 29, 2024Tier 3 - Service Providers/Vendors€2099 + VATSuper Super Early Bird Pricing - Register before 28th June to save €1400Exclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, June 29, 2024 to Saturday, August 3, 2024Tier 3 - Service Providers/Vendors€2499 + VATSuper Early Bird Pricing - Register before 2nd August to save €1000Exclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, August 3, 2024 to Saturday, September 14, 2024Tier 3 - Service Providers/Vendors€2999 + VATEarly Bird Pricing - Register before 6th September save €500Exclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, September 14, 2024 to Thursday, October 10, 2024Tier 3 - Service Providers€3499 + VATStandard PricingExclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Wednesday, May 1, 2024 to Thursday, October 10, 2024SPC & PTE Forum - PRE DAY ONLY€799 + VAT
Preparing registration...
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
We'd love to hear from you.
Contact us at +44 (0)20 3696 2920 and email [email protected], or let us know what subject area you're interested in below.